Clinical Trial Update: Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic Tumors [Phase 1]

View source ↗

Summary

Phase 1 safety and pharmacokinetic study of GW003 in metastatic tumors, including patients with chemotherapy-induced neutropenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Chemotherapy-induced Neutropenia

Drugs mentioned

• GW003

Snippet

Sponsor: Jiangsu T-Mab Biopharma Co.,Ltd | Conditions: Chemotherapy-induced Neutropenia, Metastatic Tumors | Phase 1 | Status: COMPLETED